Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia

Background Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Ou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:RADIATION ONCOLOGY 2022-08, Vol.17 (1), p.1-146, Article 146
Hauptverfasser: Slotman, Berend J., Clark, Mary Ann, Özyar, Enis, Kim, Myungsoo, Itami, Jun, Tallet, Agnès, Debus, Jürgen, Pfeffer, Raphael, Gentile, PierCarlo, Hama, Yukihiro, Andratschke, Nicolaus, Riou, Olivier, Camilleri, Philip, Belka, Claus, Quivrin, Magali, Kim, BoKyong, Pedersen, Anders, van Overeem Felter, Mette, Kim, Young Il, Kim, Jin Ho, Fuss, Martin, Valentini, Vincenzo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology. Methods Anonymized administrative data from all 0.35T-MRgRT treatment systems in Europe and Asia were extracted for patients who completed treatment from 2015 to 2020. Detailed treatment information was analyzed for all MR-linear accelerators (linac) and -cobalt systems. Results From 2015 through the end of 2020, there were 5796 completed treatment courses delivered in 46,389 individual fractions. 23.5% of fractions were adapted. Ultra-hypofractionated (UHfx) dose schedules (1-5 fractions) were delivered for 63.5% of courses, with 57.8% of UHfx fractions adapted on-table. The most commonly treated tumor types were prostate (23.5%), liver (14.5%), lung (12.3%), pancreas (11.2%), and breast (8.0%), with increasing compound annual growth rates (CAGRs) in numbers of courses from 2015 through 2020 (pancreas: 157.1%; prostate: 120.9%; lung: 136.0%; liver: 134.2%). Conclusions This is the first comprehensive study reporting patterns of utilization among early adopters of a 0.35T-MRgRT system in Europe and Asia. Intrafraction MR image-guidance, advanced motion management, and increasing adoption of on-table adaptive RT have accelerated a transition to UHfx regimens. MRgRT has been predominantly used to treat tumors in the upper abdomen, pelvis and lungs, and increasingly with adaptive replanning, which is a radical departure from legacy radiotherapy practices. Keywords: MRI-guided radiotherapy, MR-IGRT, Stereotactic body radiotherapy, SBRT, Stereotactic ablative radiation therapy, SABR, ART, oART, On-table adaptive radiation therapy, Care patterns
ISSN:1748-717X
1748-717X
DOI:10.1186/s13014-022-02114-2